US Government Backs Expanded Access Initiative for NUZ ALS Drug Candidate
Biotech firm NUZ (ASX:NUZ) has secured backing from a key U.S. health agency to launch an expanded access program for its primary drug candidate.
This initiative aims to provide eligible Amyotrophic Lateral Sclerosis (ALS) patients with access to the experimental treatment outside of standard clinical trials.
Source Attribution: Article content originally reported by Special Report. Read original story coverage on Special Report →
Medical & Health Information DisclaimerThe health and nutritional information on WelloraDaily is provided strictly for educational and informational purposes. It does not substitute for professional medical advice, clinical diagnosis, or treatment. Always consult a qualified healthcare provider regarding any health condition or dietary changes.
Elena Rostova
WelloraDaily Editorial Team
